EP0668771A4 - Behandlung von autoimmunkrankheiten durch hervorrüfen von toleranz in zellen, geweben und organen. - Google Patents

Behandlung von autoimmunkrankheiten durch hervorrüfen von toleranz in zellen, geweben und organen.

Info

Publication number
EP0668771A4
EP0668771A4 EP94901247A EP94901247A EP0668771A4 EP 0668771 A4 EP0668771 A4 EP 0668771A4 EP 94901247 A EP94901247 A EP 94901247A EP 94901247 A EP94901247 A EP 94901247A EP 0668771 A4 EP0668771 A4 EP 0668771A4
Authority
EP
European Patent Office
Prior art keywords
organs
tissues
cells
treatment
autoimmune diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94901247A
Other languages
English (en)
French (fr)
Other versions
EP0668771A1 (de
Inventor
Scott Chappel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diacrin Inc
Original Assignee
Diacrin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diacrin Inc filed Critical Diacrin Inc
Publication of EP0668771A1 publication Critical patent/EP0668771A1/de
Publication of EP0668771A4 publication Critical patent/EP0668771A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP94901247A 1992-11-09 1993-11-03 Behandlung von autoimmunkrankheiten durch hervorrüfen von toleranz in zellen, geweben und organen. Withdrawn EP0668771A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97377692A 1992-11-09 1992-11-09
US973776 1992-11-09
PCT/US1993/010534 WO1994011011A1 (en) 1992-11-09 1993-11-03 Treatment of autoimmune diseases by inducing tolerance to cells, tissues and organs

Publications (2)

Publication Number Publication Date
EP0668771A1 EP0668771A1 (de) 1995-08-30
EP0668771A4 true EP0668771A4 (de) 1998-04-01

Family

ID=25521214

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94901247A Withdrawn EP0668771A4 (de) 1992-11-09 1993-11-03 Behandlung von autoimmunkrankheiten durch hervorrüfen von toleranz in zellen, geweben und organen.

Country Status (4)

Country Link
EP (1) EP0668771A4 (de)
JP (1) JPH08503135A (de)
CA (1) CA2148835A1 (de)
WO (1) WO1994011011A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5738852A (en) * 1993-04-20 1998-04-14 Solis Therapeutics, Inc. Methods of enhancing antigen-specific T cell responses
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
US6274136B1 (en) * 1996-05-29 2001-08-14 University Of Southern California Construction and use of genes encoding pathogenic epitopes for treatment of autoimmune disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MILLER J. AND MORAHAN G.: "Peripheral T cell tolerance", ANNUAL REVIEW OF IMMUNOLOGY, vol. 10, 1992, pages 51 - 69, XP002040676 *
MORAHAN G. ET AL.: "Tolerance of class I histocompatibility antigens expressed extrathymically", NATURE, vol. 339, 22 June 1989 (1989-06-22), pages 622 - 624, XP002040674 *
SCHÖNRICH G. ET AL.: "Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction", CELL, vol. 65, no. 2, 19 April 1991 (1991-04-19), pages 293 - 304, XP002040675 *
See also references of WO9411011A1 *

Also Published As

Publication number Publication date
WO1994011011A1 (en) 1994-05-26
JPH08503135A (ja) 1996-04-09
EP0668771A1 (de) 1995-08-30
CA2148835A1 (en) 1994-05-26

Similar Documents

Publication Publication Date Title
EP0205579A4 (de) Verfahren und zusammensetzungen zur verwendung in der diagnose und behandlung autoimmuner krankheiten.
AU2645988A (en) Mild cleanser and conditioner to yield soft, smooth skin
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU3617393A (en) Improved compositions for imparting an artificial tan to human skin
EP0330496A3 (en) Skin treatment composition
PL323797A1 (en) Application of bisulphonates to prevent bone tissue loss associated with immunosuppressive therapy
GB8606913D0 (en) Treatment of sickle cell disease
AU4786093A (en) Non-peptidic surrogates of the ldv sequence and their use in the treatment of inflammation, autoimmune diseases and tumour progression
ZA898605B (en) Compositions for topical treatment of skin diseases
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
EP0716614A4 (de) Behandlung von menschlichen tumoren durch genetische transformation von menschlichen tumorzellen
NO881629L (no) Anvendelse av antigene stoffer ved behandling av lidelseri mage-tarm-kanalen.
EP0668771A4 (de) Behandlung von autoimmunkrankheiten durch hervorrüfen von toleranz in zellen, geweben und organen.
CA2283450A1 (en) Methods for treatment of scar tissue
ZA935647B (en) Treatment of sickle cell disease
EP0294538A3 (en) Use of nigericin in the treatment of viral diseases
GB8804531D0 (en) Skin treatment formulations
AU2297088A (en) Improved ovulation treatment
AU6863191A (en) Treatment of protozoal diseases
EP0444931A3 (en) Use of 3-oxygermylpropionic acid to treat and prevent diabetes-dependent autoimmune diseases
AU1162788A (en) Oxime-ethers of 2,6-dioxobicyclo-(3.3.0)octanones for treatment of heart and circulation diseases
ZA936136B (en) Treatment of skin diseases
GB9010190D0 (en) Composition for the treatment of protozoal disease and their use
GB8806116D0 (en) Treatment of skin diseases
AU4548693A (en) Treatment of skin diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950522

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RHK1 Main classification (correction)

Ipc: A61K 38/00

RHK1 Main classification (correction)

Ipc: C12N 5/10

A4 Supplementary search report drawn up and despatched

Effective date: 19980216

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980426